NBT Bank N A NY Sells 4,007 Shares of Abbott Laboratories (NYSE:ABT)

NBT Bank N A NY lowered its position in Abbott Laboratories (NYSE:ABT - Free Report) by 3.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 110,401 shares of the healthcare product maker's stock after selling 4,007 shares during the quarter. Abbott Laboratories comprises approximately 1.1% of NBT Bank N A NY's investment portfolio, making the stock its 20th biggest holding. NBT Bank N A NY's holdings in Abbott Laboratories were worth $14,645,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the company. Berkshire Bank increased its stake in shares of Abbott Laboratories by 1.9% in the first quarter. Berkshire Bank now owns 15,660 shares of the healthcare product maker's stock valued at $2,077,000 after purchasing an additional 295 shares during the period. Chicago Capital LLC increased its stake in shares of Abbott Laboratories by 15.8% during the first quarter. Chicago Capital LLC now owns 51,416 shares of the healthcare product maker's stock valued at $6,820,000 after acquiring an additional 7,030 shares during the period. Smith Shellnut Wilson LLC ADV increased its stake in shares of Abbott Laboratories by 1.9% during the first quarter. Smith Shellnut Wilson LLC ADV now owns 5,556 shares of the healthcare product maker's stock valued at $737,000 after acquiring an additional 102 shares during the period. Consilium Wealth Advisory LLC increased its stake in shares of Abbott Laboratories by 2.1% during the first quarter. Consilium Wealth Advisory LLC now owns 3,822 shares of the healthcare product maker's stock valued at $507,000 after acquiring an additional 78 shares during the period. Finally, Vivid Wealth Management LLC acquired a new position in shares of Abbott Laboratories during the first quarter valued at approximately $2,589,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Abbott Laboratories Trading Up 0.1%

Abbott Laboratories stock traded up $0.07 during midday trading on Wednesday, reaching $132.35. The stock had a trading volume of 4,950,337 shares, compared to its average volume of 6,109,754. The firm's fifty day simple moving average is $131.80 and its two-hundred day simple moving average is $126.62. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.78 and a quick ratio of 1.27. The firm has a market cap of $230.27 billion, a price-to-earnings ratio of 17.17, a PEG ratio of 2.51 and a beta of 0.73.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its earnings results on Wednesday, April 16th. The healthcare product maker reported $1.09 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.89% and a return on equity of 19.01%. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.38 billion. Equities analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a $0.59 dividend. The ex-dividend date is Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.78%. Abbott Laboratories's dividend payout ratio (DPR) is currently 30.61%.

Insider Buying and Selling at Abbott Laboratories

In other Abbott Laboratories news, Director Sally E. Blount sold 2,600 shares of the business's stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $129.66, for a total value of $337,116.00. Following the transaction, the director now owns 34,058 shares in the company, valued at $4,415,960.28. The trade was a 7.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.46% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Morgan Stanley raised their price objective on shares of Abbott Laboratories from $117.00 to $127.00 and gave the company an "equal weight" rating in a research note on Thursday, April 17th. Bank of America raised their price objective on shares of Abbott Laboratories from $133.00 to $150.00 and gave the company a "buy" rating in a research note on Monday, March 10th. Royal Bank Of Canada raised their price objective on shares of Abbott Laboratories from $140.00 to $145.00 and gave the company an "outperform" rating in a research note on Thursday, April 17th. Barclays lifted their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the stock an "overweight" rating in a research report on Thursday, April 17th. Finally, Piper Sandler restated an "overweight" rating and issued a $145.00 price target (up previously from $133.00) on shares of Abbott Laboratories in a research report on Thursday, April 17th. Six investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Abbott Laboratories has a consensus rating of "Moderate Buy" and an average price target of $142.61.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.